Nothing negative in today's PR, IMO. Alcohol-free Docetaxel was never expected to be a big-selling product like Bendeka.
EGRX shares are quite volatile compared to a typical biotech company with a comparable EV. They often move 5% or more in a given day with no news whatsoever.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”